IMPLICATION OF HUMAN FC RECEPTORS POLYMORPHISM IN CHILDHOOD IMMUNE THROMBOCYTOPENIC PURPURA
Keywords:
FCGR POLYMORPHISM, IMMUNE THROMBOCYTOPENIC PURPURA, CHILDREN, PLATELETSAbstract
Immune thrombocytopenic purpura (ITP) is the most frequent form of autoimmune disease in childhood, characterized by thrombocytopenia (platelet count <150·109/L) with otherwise normal cell lineages. One of the main mechanisms is the platelet destruction by phagocytic cells, covered by human Fc receptors (FCGR). The FCR family involves 3 classes of receptors: FCGR1A, 1B, and 1C; FCGR2A, 2B, and 2C; FCGR3A and 3B, all present on chromosome 1q23-24. The response to ITP treatment may be influenced by the polymorphism of the FCGR3A gene, which contributes to different levels of destruction of antibody - bound platelets. Material and methods: We report the results of FCGR2/3 polymorphic genotypes in 16 children with ITP admitted at the “Sf. Maria” Emergency Children’s Hospital, Iasi, Romania, treated with corticosteroids, intravenous immunoglobulin (IVIg) or both, or conservative treatment, with a minimum of one year follow up. Results: We identified 9/16 patients with FCGR2C ORF haplotypes, 8 in heterozygous state and one in homozygous state, and 15/16 patients with FCGR2A-His166 variant. While it was previously reported that classical FCGR2C-ORF and 2B.4 variants correlate with the transient form of ITP and a good response to IVIg, in our sample it was present only in 3 patients, who had limited course of disease and a good response to IVIg. 5 patients were heterozygotes for FCGR2C-p.Gln62Trp, all of them developing an acute form, a good response to IVIg and no relapses. Furthermore, it has been demonstrated an association between FCGR genotypes characterized by increased immunoglobulin binding activity (FCGR3A allele V158 and FGCGR3B allele NA1) and chronic children ITP. In our study, only 2/16 patients express NA1 in homozygous state, one of them developing persistent ITP, while the other responded well to the treatment and did not relapse. Conclusions: Genetic influences contribute to the pathogenesis of ITP in children and response to IVIg. We evaluated the genetic risk factors in the FCGR2/3 locus that are associated with predisposition to limited course and a favorable response to IVIg in ITP in children. However, confirmation in a larger prospectively recruited cohort of children with ITP is needed.
References
2. Bruin M, Bierings M, Uiterwaal C, et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br J Haematol 2004; 127: 561-567 / doi:10.1111/j.1365-2141.2004.05235.x.
3. Arepally, G, McKenzie, S.E, Jiang, X.-M, Poncz, M, Cines, D.B. FcγRIIA H/R131 Polymorphism, Subclass-Specific IgG Anti-Heparin/Platelet Factor 4 Antibodies and Clinical Course in Patients With Heparin-Induced Thrombocytopenia and Thrombosis. Blood 1997; 89: 370-375 / doi:10.1182/blood.V89.2.370.
4. Niederer HA, Willcocks LC, Rayner TF, et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet 2010; 19: 3282-3294 / doi:10.1093/ hmg/ddq216.
5. Mahaweni NM, Olieslagers TI, Rivas IO, et al. A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism. Sci Rep 2018; 8: 15983 / doi:10.1038/s41598-018-34258-1.
6. Fujimoto, T.T, Inoue, M, Shimomura, T, Fujimura, K. Involvement of Fc gamma receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol 2001; 115: 125-130 / doi:10.1046/j.1365-2141.2001.03109.x.
7. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombo-cytopenic purpura. The Journal of Pediatrics 2002; 141: 683-688 / doi:10.1067/mpd.2002.128547.
8. Resmerita I, Cozma RS, Popescu R, et al. Genetics of Hearing Impairment in North-Eastern Romania-A Cost-Effective Improved Diagnosis and Literature Review. Genes 2020; 11 / doi:10.3390/genes11121506.
9. Nagelkerke SQ, Tacke CE, Breunis WB, et al. Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression. Genes and immunity 2015; 16: 422-429 / doi:10.1038/ gene.2015.25.
10. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14: 215-221 / doi:10.1016/0167-5699(93) 90166-I.
11. Manger, K, Repp, R, Jansen, M, et al. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis 2002; 61: 786-792 / doi:10.1136/ard.61.9.786.
12. Vedeler CA, Myh K.M, Nyland H. Fc receptors for immunoglobulin G-a role in the pathogenesis of Guillain-Barre syndrome and multiple sclerosis. J Neuroimmunol 2001; 118: 187-193 / doi:10.1016/s0165-5728(01)00344-7.
13. Nagelkerke SQ, Tacke CE, Breunis WB, et al. Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. Front Immunol 2019; 10: 185 / doi:10.3389/fimmu.2019.00185.
14. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991; 147: 1338-1343.
15. Foster CB, Zhu S, Erichsen HC, et al. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 2001; 113: 596-599 / doi:10.1046/j.1365-2141.2001.02807.x.
16. Lejeune J, Piegu B, Gouilleux-Gruart V, Ohresser M, Watier H, Thibault G. FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymor-phisms in a Caucasian population. MAbs 2012; 4: 784-787 / doi:10.4161/mabs.22287.
17. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
18. Bredius RG, Fijen CA, De Haas M, et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 1994; 83: 624-630.
19. Sanders LA, Feldman RG, Voorhorst-Ogink MM, et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63: 73-81 / doi:10.1128/iai.63.1.73-81.1995.
20. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 1348-1354 / doi:10.1172/JCI118552.
21. Li G, Gao L, Ma R, Tian W, Mingzhi L. Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis. Scand J Immunol 2019; 89: e12758 / doi:10.1111/sji.12758.
22. Carcao MD, Blanchette VS, Wakefield CD, et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 2003; 120: 135-141 / doi:10.1046/j.1365-2141. 2003. 04033.x.
23. Papagianni A, Economou M, Tragiannidis A, et al. FcgammaRIIa and FcgammaRIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome. Blood Coagul Fibrinolysis 2013; 24: 35-39 / doi:10.1097/ MBC. 0b013e328359bc3b.
24. Zakaria M, Al-Akhras A, Hassan T, et al. FcgammaRIIa and FcgammaRIIIa genes polymorphism in Egyptian children with primary immune thrombocytopenia. Hematol Transfus Cell Ther 2023; 45: 58-65 / doi:10.1016/j.htct.2021.05.007.
25. Breunis WB, van Mirre E, Bruin M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008; 111: 1029-1038 / doi:10.1182/blood-2007-03-079913.
26. Schmidt DE, Heitink-Polle KMJ, Laarhoven AG, et al. Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-gamma receptor polymorphisms. Blood Adv 2019; 3: 2003-2012 / doi:10.1182/ blood advances.2019000068.
27. Heitink-Polle KMJ, Uiterwaal C, Porcelijn L, et al. Intravenous immunoglobulin vs. observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood 2018; 132: 883-891 / doi:10.1182/blood-2018-02-830844.
28. Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW. Genetic Variation in Low-To-Medium-Affinity Fcgamma Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine. Front Immunol 2019; 10: 2237 / doi:10.3389/ fimmu.2019.02237.
29. Su K, Wu J, Edberg JC, McKenzie, S.E, Kimberly, R.P. Genomic organization of classical human low-affinity Fcgamma receptor genes. Genes Immun 2002, 3 Suppl 1, S51-56, doi:10.1038/sj.gene.6363879.
30. Gavrilovici C, Oprea L. Clinical ethics, Research ethics and community ethics – The moral triad of nowadays society. Revista Română de Bioeticǎ 2013; 11: 3.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
